Login to Your Account



Trius $30M Private Placement Boosts Torezolid Phase III Trial

By Staff Reports


Friday, May 27, 2011
Trius Therapeutics Inc. raised $30 million through a private placement of stock and warrants – money that will be used to support Phase III trials of antibiotic torezolid.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription